Navigation Links
Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe

CYPRESS, Calif. and MADISON, N.J., Nov. 1, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the CE mark and European availability of the Simplexa Flu A/B & RSV Direct test on the 3M™ Integrated Cycler.  The new test, from the company's Focus Diagnostics business, uses a proprietary technique to eliminate nucleic-acid sample extraction, a time-consuming process required by other molecular test products, for faster results reporting.

"Simplexa Direct chemistry employs a novel technology that overcomes a critical limitation found in most molecular test kits on the market: the need for extraction of nucleic acids," said Maurice Exner, Ph.D., vice president of research and development, Focus Diagnostics.  "With this advance, molecular testing will be far easier and faster for labs to perform than before. We believe the Simplexa Direct method is an important step toward enabling a greater range of healthcare professionals to access quality molecular testing. We look forward to introducing our first Simplexa Direct product, for influenza and respiratory syncytial virus testing, to laboratories in Europe."

Nucleic-acid extraction is a process requiring specialized molecular equipment and trained personnel. It involves extracting DNA or RNA from a blood, plasma or other specimen type for testing. The nucleic-acid extraction process, used in most commercial molecular test kits, can add approximately 60 to 90 minutes to total testing time. Focus Diagnostics has replaced the process with a proprietary reaction-mix technique. The company expects to use the proprietary technology in future Simplexa products.

Simplexa Flu A/B & RSV Direct is an addition to the influenza and respiratory franchise of award-winning FDA-cleared and CE-marked assays available through Focus Diagnostics.

"The future of influenza testing and, indeed, all respiratory virus testing is molecular. This is because molecular testing offers the potential to provide both high sensitivity and faster turnaround time. Clinicians need an accurate result in a timely manner to help them make the best management decisions for their patients," said Jay M. Lieberman, M.D., medical director, infectious disease, for Quest Diagnostics and Focus Diagnostics. "As technology continues to evolve, molecular testing will become easier and more accessible to a great number of labs and physicians."

About Simplexa

Focus Diagnostics, a wholly-owned business of Quest Diagnostics, develops and manufactures the Simplexa line of molecular test products operating on the 3M™ Integrated Cycler, a compact, portable testing platform, as part of an exclusive global collaboration with 3M™.  Simplexa was the first test kit to be FDA cleared for aiding in the detection and differentiation of the 2009 H1N1 influenza virus, in May 2010. Additional FDA-cleared Simplexa tests aid the detection of influenza A and B and respiratory syncytial virus. Several other Simplexa-branded tests, including for Clostridium difficile, Epstein Barr and BK viruses, are CE marked and distributed in Europe. In 2011, the Simplexa/3M technology won a gold Medical Design Excellence Award in the in vitro diagnostics category and an Edison Award for new science and medical diagnostic product.

To learn more about or to order Simplexa and other Focus Diagnostics tests, please contact Focus Diagnostics at 800-445-0185 (U.S.) or +49-6026-9499540 (Europe), or visit or

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at Follow us at and

Wendy Bost (Media): 973-520-2800
Kathleen Valentine (Investors): 973-520-2900

SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
2. Questcor Reports Third Quarter Financial Results
3. Alquest Announced as MedNet Solutions First iMedNet CRO Partner
4. Quest Introduces Its Next Generation AlphaView 4MP Medical LCD
5. Quest Diagnostics to Release Third Quarter 2011 Financial Results
6. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
7. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
8. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
9. St. Jude Childrens Research Hospital Discovery Aided Quest for Adult Cancer Drug
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
11. PCAN Calls On Federal Government to Reconsider Preliminary Approval of Texas Medicaid Waiver Request
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... SALT LAKE CITY , Dec. 1, 2015  Booth ... at booth #3506 during the annual meeting of the Radiological ... Chicago this year. Based in ... Imaging Components business of Varian Medical Systems (NYSE: VAR ... high voltage connectors, ionization chambers and solid state automatic exposure ...
(Date:12/1/2015)... -- Olea Sensor Networks, a leader in intelligent sensors and analytic software for sensor network-based systems, ... real-time data collection of vital signs. Photo ... ... ... ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... continuing medical education (CME), today announced that the first annual School of Gastrointestinal ... , “The prevention, detection and treatment of gastrointestinal cancers are undergoing transformational change, ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS ... 2015 Golden Bridge Business Awards under the New Products and Services category for ... based sample management software that helps labs organize data and track ...
(Date:12/1/2015)... CHICAGO (PRWEB) , ... December 01, 2015 , ... ... risk quantification and optimization of adjunctive imaging is the focus of numerous abstracts ... (RSNA) meeting, November 29-December 4, 2015. Nine abstracts highlight the use of ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):